The U.S. Food and Drug Administration has accepted Ionis Pharmaceuticals Inc.'s (NASDAQ: IONS) new drug application for zilganersen, an experimental ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE